<DOC>
	<DOCNO>NCT01366209</DOCNO>
	<brief_summary>PIPF-016 ( ASCEND ) Randomized , Double-Blind , Placebo Controlled , Phase 3 Study Efficacy Safety Pirfenidone Patients Idiopathic Pulmonary Fibrosis . The study objectives confirm treatment effect pirfenidone compare placebo change percent predict forced vital capacity ( % FVC ) patient idiopathic pulmonary fibrosis ( IPF ) , confirm safety treatment pirfenidone compare placebo patient IPF .</brief_summary>
	<brief_title>Efficacy Safety Pirfenidone Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Select 1 . Diagnosis idiopathic pulmonary fibrosis ( IPF ) , consistent ATS 2011 Guidelines , 648 month ' duration 2 . Age 40 80 randomization 3 . Percent Forced Vital Capacity ( % FVC ) ≥50 % ≤90 % screen 4 . Percent Carbon Monoxide Diffusing Capacity ( % DLCO ) ≥30 % ≤90 % screening Select 1 . Forced expiratory volume one second ( FEV1 ) /FVC ratio &lt; 0.8 administration bronchodilator Screening 2 . Expected receive lung transplant within 1 year randomization , patient site United States , lung transplant wait list randomization 3 . Known explanation interstitial lung disease 4 . History asthma chronic obstructive pulmonary disease 5 . Active infection 6 . Ongoing IPF treatment include investigational therapy , immunosuppressant , cytokine modulate agent 7 . History unstable deteriorate cardiac pulmonary disease ( IPF ) within previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pirfenidone</keyword>
	<keyword>ASCEND</keyword>
	<keyword>IPF</keyword>
	<keyword>FVC</keyword>
</DOC>